Management of inadequate response and adverse effects to dupilumab in atopic dermatitis

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, skin-pain, and sleep disturbances. Currently, dupilumab is the only U.S. FDA approved systemic therapy and biologic medication for moderate-to-severe AD in adults and children. There is a sparsity of literature available on determining treatment failure with dupilumab and the next steps healthcare providers can take to treat AD. Individual goals and quality of life, and not just body surface area should be considered when defining treatment failure.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research